A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kevin Kalinsky, Melissa Kate Accordino, Codruta Chiuzan, Prabhjot Singh Mundi, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N. Baer, Sun Young Oh, Amelia Bruce Zelnak, Kari Braun Wisinski, Eleni Andreopoulou, William John Gradishar, Erica Stringer-Reasor, Sonya A. Reid, Anne O'Dea, Ruth O'Regan, Katherine D. Crew, Dawn L. Hershman
Institutions: Emory University, Winship Cancer Institute, Columbia University, Northwell Health, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Icahn School of Medicine at Mount Sinai, Stony Brook University, Montefiore Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Weill Cornell Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Alabama, University of Alabama at Birmingham, Vanderbilt University Medical Center, University of Kansas Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novartis
OpenAlex ID: W4293083585